CARCINOMA, NON-SMALL-CELL LUNG

This early-phase study tested an experimental drug called QEQ278 in 30 adults with advanced solid tumors, including lung, kidney, esophageal, and head and neck cancers. The main goal was to check the drug's safety and find the right dose. The trial was terminated early, so result…

This study tested a drug called PF-08046052/SGN-EGFRd2 in people with advanced solid tumors that could not be removed or had spread. The goal was to find a safe dose and check for side effects. The trial was terminated early, so results are limited. It involved 68 participants wi…

This study tested a drug called MORAb-202 in people with a type of advanced lung cancer (non-small cell lung cancer adenocarcinoma) that had spread and stopped responding to other treatments. The drug works like a guided missile, targeting a protein called folate receptor alpha o…

This study looked at several immunotherapy drug combinations for people with advanced non-small cell lung cancer that had spread. It included two groups: those who had not yet received treatment and those whose cancer had worsened after prior therapy. The goal was to see if these…

This early-stage study tested a new drug called PF-08046037, given alone or with another drug (sasanlimab), in people with advanced lung, head and neck, melanoma, or pancreatic cancers. The goal was to check safety and how the body processes the drug. Only 8 people took part befo…

This study tested a new drug called bemcentinib combined with standard chemotherapy and immunotherapy for people with advanced non-squamous non-small cell lung cancer. The goal was to see if the combination was safe and could shrink tumors, especially in patients with a specific …

This study tested sasanlimab, an immunotherapy drug, combined with other targeted treatments for people with advanced non-small cell lung cancer (NSCLC). The trial was stopped early, but some participants in one group completed treatment. The goal was to see if the combinations w…

This study tested a new drug called BAT3306 against the standard drug Keytruda, both given with chemotherapy, for people with advanced non-squamous non-small cell lung cancer. The goal was to see if BAT3306 works as well and is as safe as Keytruda. The study was terminated early,…

This early-phase study tested a new drug, PF-07284890, alone or with another drug, in people with advanced solid tumors (like melanoma or lung cancer) that have a specific BRAF V600 gene change, including those that spread to the brain. The main goals were to check safety, how th…

This study tested a new drug called felmetatug vedotin, alone or with pembrolizumab, in people with advanced solid tumors (like ovarian, breast, lung, and others). The goal was to check safety and find the right dose. The trial was terminated early, so results are limited.

This study tested a new targeted pill, pralsetinib, against standard chemotherapy for people with a specific type of advanced lung cancer (RET fusion-positive) who had not yet received treatment. The goal was to see if the targeted drug could delay cancer growth better than chemo…

This study tested a new drug called TRX-221 in people with a specific type of advanced lung cancer (EGFR mutant NSCLC) that had stopped responding to standard treatments. The goal was to see if TRX-221 was safe and could shrink tumors. The trial was stopped early after enrolling …

This early-stage study tested whether a special MRI scan (using xenon gas) can create a map of working lung areas to guide radiation away from healthy tissue. The goal was to reduce lung damage and improve quality of life for people with non-small cell lung cancer. Only 9 patient…

This study aimed to see if genome sequencing could help doctors choose better treatments for people with multiple lung cancer tumors. It planned to enroll 100 adults with early-stage lung adenocarcinoma. However, the study was stopped early, so no clear conclusions were reached.

This early-phase study used special PET scans to see where an experimental drug (BI 754111) goes in the body and how much reaches tumors in people with advanced non-small cell lung cancer or head/neck cancer. Only 8 participants were enrolled before the study was stopped. The mai…